Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

Clinical trial NCT04338061 · TERMINATED

Trial details

NCT number: NCT04338061
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Relapsing Multiple Sclerosis

Start date: 2020-07-02
Primary completion: 2023-10-02
Enrollment: 1166

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.